Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237250 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT00237250 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 171 participants.
The verdict
NCT00237250, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.
Interventions
- DRUG vildagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00237250
The ClinicalTrials.gov registry entry for NCT00237250 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vildagliptin is the first listed.
NCT00237250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00237250 about?
NCT00237250 is a clinical study titled "Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance". The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.
What is the current status of trial NCT00237250?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2005-10. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00237250?
The interventions under investigation include: vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00237250?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.